Press Release Aug 21 2025
Filed with NSE · · 5 pages · English
Summary by 6ix AI
Piramal Pharma Limited has issued a press release regarding a joint investment with NewAmsterdam Pharma to enhance oral solid dosage production capabilities at its Sellersville, Pennsylvania site. The investment will create a dedicated suite for fixed dose combination products, aimed at meeting high commercial demand for a specific investigational drug therapy.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Piramal Pharma
- Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site
- Press Release Jul 28 2025
- Piramal Pharma Limited Announces Results for Q1FY26
- Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan
- Press Release May 14 2025
Later from Piramal Pharma
- Piramal Pharma Publishes FY2025 Sustainability Report, Outlining Performance and Decarbonization Glidepath
- Piramal Pharma Solutions Supports George Medicines in Developing its New Drug for Hypertension, WIDAPLIK™ (telmisartan, amlodipine and indapamide)
- Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility
- Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities
- Piramal Pharma Limited Announces Results for Q2 and H1 FY26
Follow Piramal Pharma into a list and get an email when it puts out news.
Follow Piramal Pharma